Partnership includes training program for medical students, focused on how to analyze clinical trial diversity data ATLANTA, GA – MARCH 31, 2025 – Morehouse School of Medicine (MSM) and the Catalyzing ...

This article examines post-market drug safety, highlighting surveillance mechanisms, regulatory responses, and case studies ...

called the cosmic microwave background, the DESI data shows that dark energy’s impact could be weakening over time. “If this continues then eventually dark energy will not be the dominant forc ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

Dark spots on the skin are usually not a cause for concern, but some people may choose to get rid of them for cosmetic reasons through laser treatment, microdermabrasion, and other methods. Dark ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Mer­ck has struck a li­cens­ing deal for a car­dio­vas­cu­lar drug with Jiang­su Hen­grui Phar­ma­ceu­ti­cals, the lat­est in a flood of Chi­na deals be­ing made by … ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...